Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer urges NHS CCGs to consider Sativex treatment for MS

Bayer urges NHS CCGs to consider Sativex treatment for MS

10th October 2014

Bayer has urged NHS clinical commissioning groups (CCGs) to continue to consider Sativex as a potential treatment pathway for patients with multiple sclerosis (MS), despite clinical guidance to the contrary.

According to the National Institute for Health and Care Excellence's (Nice's) recommendations for the management of MS in primary and secondary care, Sativex – a cannabis-derived oromucosal spray – is not sufficiently cost-effective for NHS treatment.

However, Bayer hopes CCGs will consider funding the drug outside of national guidelines, based on its proven benefits and a favourable pricing framework.

For NHS buyers, the company covers the cost of a patient's first pack of Sativex, meaning the health service does not pay to identify whether or not an individual will respond to the treatment.

Dr Martin Duddy, consultant in neurology at the Royal Victoria Infirmary in Newcastle, called it "disappointing" that Nice had not recommended the drug, which studies have demonstrated to be "very effective" in some patients.

"I am hoping that local commissioning groups will consider funding the drug … where other treatment options have been exhausted," he concluded.ADNFCR-8000103-ID-801753720-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.